Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. hbmp-700

HbMP-700

The World's First Safe and Efficacious Human Blood Substitute: HbMP-700, a Haemoglobin based oxygen carrier, based on bovine blood.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 HbMP-700 project word cloud

Explore the words cloud of the HbMP-700 project. It provides you a very rough idea of what is the project "HbMP-700" about.

good    clinical    cc    adding    economic    plan    risk    85    shortages    healthcare    voluntary    feasibility    15nb    global    cell    substitute    extracted    blood    military    treat    35    first    regulatory    trial    malignancies    victims    afford    excellent    frequent    standard    human    gcp    patient    peak    manufacturing    preclinical    red    lyophilized    markets    sufficient    patented    donors    transformed    bears    critical    conduct    trials    transfusions    annually    world    compensate    weeks    representing    surgery    700    natural    market    sme    subsequently    demand    few    source    compliant    laboratory    conflicts    supply    powder    sales    gmp    types    stored    care    safety    infection    technological    severe    introduction    leads    patients    slaughterhouse    match    donor    develops    25    business    rbc    infections    bn    countries    humans    proof    hbmp    nearly    conducting    months    disasters    ery    unlimited    contamination    accidents    bovine    situation    haematological    mio    total    purification   

Project "HbMP-700" data sheet

The following table provides information about the project.

Coordinator		 CC-ERY GMBH 

Organization address
address: ROBERT-ROSSLE-STRASSE 10
city: BERLIN
postcode: 13125
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Germany [DE]
 Project website http://www.cc-ery.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-01-01   to  2017-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CC-ERY GMBH DE (BERLIN) coordinator 50˙000.00

Map

 Project objective

CC-Ery GmbH develops HbMP-700, the world’s first substitute for human blood as a source for red blood cell (RBC) transfusions. 85 Mio. RBC transfusions are used p.a., representing a 10-15nb€ market. They are used to compensate for blood loss during surgery, treat patients with haematological malignancies, as well as victims of accidents, natural disasters, and military conflicts. The only source for RBC transfusions today are voluntary human blood donors. This leads to frequent supply shortages in the EU and other major healthcare markets. Donor blood must match patient blood. It can only be stored a few weeks, adding to the critical supply situation. Developing countries face a more severe situation as they cannot afford the standard of care of the developed world. In addition, human blood bears the risk of contamination with infections. HbMP-700 is extracted from bovine blood – a nearly unlimited, low cost supply source. It is transformed by a patented purification and manufacturing method to a lyophilized powder that is as effective as RBC transfusions from human blood, but bears no risk of infection, can be stored for months, and can be given to patients of all blood types. Bovine blood from one major EU slaughterhouse is sufficient to produce enough HbMP-700 to supply global demand for RBC transfusions. CC-Ery implemented the manufacturing method on a laboratory scale and is currently conducting preclinical trials, so far with excellent results. The objective of the SME Phase I project is to develop a business plan for the market introduction of HbMP-700. For this, a technological, regulatory, and economic feasibility analysis will be conducted. In Phase II, it is planned to build up a GMP (Good Manufacturing Practice) compliant manufacturing process and subsequently conduct a GCP (Good Clinical Practice) safety and proof of concept trial in humans. Total cost to market is estimated to be € 25-35 Mio. Peak sales are estimated to be more than € 1 bn. annually.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HBMP-700" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HBMP-700" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More  

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

FAIR (2020)

FLAGELLIN AEROSOL THERAPY AS AN IMMUNOMODULATORY ADJUNCT TO THE ANTIBIOTIC TREATMENT OF DRUG-RESISTANT BACTERIAL PNEUMONIA

Read More